Etanercept: Long-term clinical experience in rheumatoid arthritis and other arthritis

Expert Opinion on Pharmacotherapy

Volumn 8, Issue 9, 2007, Pages 1373-1397

  Cobo Ibanez T ^a   Martín Mola, Emar ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Ankylosing spondylitis; Clinical trial; Efficacy; Etanercept; Juvenile idiopathic arthritis; Methotrexate; Psoriatic arthritis; Rheumatoid arthritis; Safety

Indexed keywords

ADALIMUMAB; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DIGOXIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GAMMA INTERFERON; GLUCOCORTICOID; INFLIXIMAB; LAMIVUDINE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RIBAVIRIN; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; WARFARIN; ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN G; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ANKYLOSING SPONDYLITIS; AREA UNDER THE CURVE; ASPERGILLOSIS; ASTHENIA; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CANDIDIASIS; CLINICAL TRIAL; COCCIDIOIDOMYCOSIS; COMBINATION CHEMOTHERAPY; CRYPTOCOCCOSIS; CYTOMEGALOVIRUS INFECTION; DEMYELINATING DISEASE; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG FEVER; DRUG HALF LIFE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FETUS MALFORMATION; HEART FAILURE; HEPATITIS B; HEPATITIS C; HISTOPLASMOSIS; HODGKIN DISEASE; HUMAN; IMMUNE RESPONSE; INFECTION; INFECTIOUS MONONUCLEOSIS; JUVENILE RHEUMATOID ARTHRITIS; LISTERIOSIS; LONG TERM CARE; LUPUS LIKE SYNDROME; LYMPHOMA; MONOTHERAPY; MULTIPLE SCLEROSIS; MYCOBACTERIOSIS; MYELITIS; MYOSITIS; NOCARDIOSIS; NONHODGKIN LYMPHOMA; NONHUMAN; OPPORTUNISTIC INFECTION; OPTIC NEURITIS; PHARMACOLOGICAL BLOCKING; PHLEBITIS; PNEUMOCYSTOSIS; POLYNEUROPATHY; PREECLAMPSIA; PREGNANCY; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; SIDE EFFECT; SOLID TUMOR; SPONTANEOUS ABORTION; TUBERCULOSIS; WEIGHT REDUCTION; ARTHRITIS; CONTROLLED CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; RANDOMIZED CONTROLLED TRIAL;

ANTIRHEUMATIC AGENTS; ARTHRITIS; ARTHRITIS, RHEUMATOID; DOUBLE-BLIND METHOD; HUMANS; IMMUNOGLOBULIN G; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 34250827839     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.8.9.1373     Document Type: Review

References (163)

1. CHU CQ, FIELD M, FELDMANN M, MAINI RN: Localization of tumor necrosis factor α in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum. (1991) 34:1125-1132.
2. CAMUSSI G, LUPIA E: The future role of anti-tumour necrosis factor (TNF) products in the treatment of rheumatoid arthritis. Drugs (1998) 55:613-620.
3. BONIFATI C, AMEGLIO F: Cytokines in psoriasis. Int. J. Dermatol. (1999) 38:241-251.
4. BONIFATI C, CARDUCCI M, CORDIALI FEI P et al.: Correlated increases of tumour necrosis Factor-α, interleukin-6 and granulocyte monocyte-colony stimulating factor levels in suction blister fluids and sera of psoriatic patients: relationships with disease severity. Clin. Exp. Dermatol. (1994) 19:383-387.
5. GRATACOS J, COLLADO A, FILELLA X et al.: Serum cytokines (IL-6, TNF-α, IL-1 β and IFN-γ) in ankylosing spondylitis: a dose correlation between serum IL-6 and disease activity and severity. Br. J. Rheumatol. (1994) 33:927-931.
6. FELDMANN M: The cytokine network in rheumatoid arthritis: definition of TNF α as a therapeutic target. J. R. Coll. Physicians. Lond. (1996) 30:560-570.
7. BUTLER DM, MAINI RN, FELDMANN M, BRENNAN FM: Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti TNF-α antibody with the interleukin-1 receptor antagonist. Eur. Cytokine Netw. (1995) 6:225-230.
8. DAVIS JC: Understanding the role of tumor necrosis factor inhibition in ankylosing spondylitis. Semin. Arthritis Rheum. (2004) 34:668-677.
9. HARAOUI B: Differentiating the efficacy of the tumor necrosis factor inhibitors. Semin. Arthritis Rheum. (2005) 34(5 Suppl. 1):7-11.
10. BECKHAM JC, CALDWELL DS, PETERSON BL et al.: Disease severity in rheumatoid arthritis: relationships of plasma tumor necrosis factor-α, soluble interleukin 2-receptor, soluble CD4/CD8 ratio, neopterin, and fibrin D-dimer to traditional severity and functional measures. J. Clin. Immunol. (1992) 12:353-361.
11. BRAUN J, BOLLOW M, NEURE L et al.: Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum. (1995) 38:499-505.
12. BRANDT J, HAIBEL H, CORNELY D et al.: Successful treatment of active ankylosing spondylitis with the antitumor necrosis factor α monoclonal antibody infliximab. Arthritis Rheum. (2000) 43:1346-1352.
13. CATRINA AI, LAMPA J, ERNESTAM S et al.: Anti-tumour necrosis factor (TNF)-α therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis. Rheumatology (Oxford) (2002) 41:484-489.
14. CATRINA AI, TROLLMO C, AF KLINT E et al.: Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joint. Arthritis Rheum. (2005) 52:61-71.
15. VAN DEN BRANDE JM, BRAAT H, VAN DEN BRINK GR et al.: Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology (2003) 124:1774-1785.
16. CATRINA AI, AF KLINT E, ERNESTAM S et al.: Anti-tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis. Arthritis Rheum. (2006) 54:76-81.
17. BOIRIVANT M, MARINI M, DI FELICE G et al.: Lamina propria T cells in Crohn's disease and other gastrointestinal inflammation show defective CD2 pathway-induced apoptosis. Gastroenterology (1999) 116:557-565.
18. GOTTLIEB AB, CHAMIAN F, MASUD S et al.: TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. J. Immunol. (2005) 175:2721-2729.
19. LIZZUL PF, APHALE A, MALAVIYA R et al.: Differential expression of phosphorylated NF-kappaB/RelA in normal and psoriatic epidermis and downregulation of NF-kappaB in response to treatment with etanercept. J. Invest. Dermatol. (2005) 124:1275-1283.
20. KORTH-BRADLEY JM, RUBIN AS, HANNA RK, SIMCOE DK, LEBSACK ME: The pharmacokinetics of etanercept in healthy volunteers. Ann. Pharmacother. (2000) 34:161-164.
21. KREMER J, SPENCER-GREEN G, HANNA R, KORTH-BRADLEY J: Embrel (etanercept) pharmacokinetics in patients with rheumatoid arthritis [abstract]. Arthritis Rheum. (2000) 43(Suppl): S976.
22. YIM DS, ZHOU H, BUCKWALTER M, NESTOROV I, PECK CC, LEE H: Population pharmacokinetic analysis and simulation of the time-concentration profile of etanercept in pediatric patients with juvenile rheumatoid arthritis. J. Clin. Pharmacol. (2005) 45:246-256.
23. NESTOROV I, ZITNIK R, DEVRIES T, NAKANISHI AM, WANG A. BANFIELD C: Pharmacokinctics of subcutaneously administered etanercept in subjects with psoriasis. Br. J. Clin. Pharmacol. (2006) 62:435-445.
24. ZHOU H, BUCKWALTER M, BONI J et al.: Population-based pharmacokinetics of the soluble TNFr etanercept: a clinical study in 43 patients with ankylosing spondylitis compared with post hoc data from patients with rheumatoid arthritis. Int. J. Clin. Pharmacol. Ther. (2004) 42:267-276.
25. NESTOROV I: Clinical pharmacokinetics of TNF antagonists: how do they differ? Semin. Arthritis Rheum. (2005) 34(5 Suppl. 1):12-18.
26. ZHOU H: Clinical pharmacokinetics of etanercept: a fitlly humanized soluble recombinant tumor necrosis factor receptor fusion protein. J. Clin. Pharmacol. (2005) 45:490-497.
27. KEYSTONE EC, SCHIFF MH, KREMER JM et al.: Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. (2004) 50:353-363.
28. NESTOROV I, LEBSACK M, DEVRIES T, BURGE T: Pharmacokinetics of etanercept after once weekly subcutaneous administration of 50 mg doses to rheumatoid arthritis patients [abstract]. Ann. Rheum. Dis. (2003) 62(Suppl. 1):182.
29. VAN DER HEIJDE D, DA SILVA JC, DOUGADOS M et al.: Etanercept Study 314 Investigators. Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis. Ann. Rheum. Dis. (2006) 65:1572-1577.
30. LEE H, KIMKO HC, ROGGE M, WANG D, NESTOROV I, PECK CC: Population pharmacokinetic and pharmacodynamic modeling of etanercept using logistic regression analysis. Clin. Pharmacol Ther. (2003) 73:348-365.
31. SORAN O, FELDMAN AM, SCHNEIDER VM, HANNA R, MANN DL, KORTH-BRADLEY JM: The pharmacokinetics of etanercept in patients with heart failure. Br. J. Clin. Pharmacol. (2001) 51:191-192.
32. ZHOU H, PARKS V, PATAT A, LE COZ F, SIMCOE D, KORTH-BRADLEY J: Absence of a clinically relevant interaction between etanercept and digoxin. J. Clin. Pharmacol. (2004) 44:1244-1251.
33. ZHOU H, PATAT A. PARKS V, BUCKWALTER M, METZGER D, KORTH-BRADLEY J: Absence of a pharmacokinetic interaction between etanercept and warfarin. J. Clin. Pharmacol. (2004) 44:543-550.
34. GENOVESE MC, COHEN S, MORELAND L et al.: Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum. (2004) 50:1412-1419.
35. ZHOU H, MAYER PR, WAJDULA J, FATENEJAD S: Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis. J. Clin. Pharmacol. (2004) 44:1235-1243.
36. MORELAND LW, MARGOLIES G, HECK LW, SAWAY A, BLOSCH C, HANNA R, KOOPMAN WJ: Recombinant soluble tumor necrosis factor receptor (p80) fusion protein: toxicity and dose finding trial in refractory rheumatoid arthritis. J. Rheumatol (1996) 23:1849-1855.
37. MORELAND LW, BAUMGARTNER SW, SCHIFF MH et al.: Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor (p75)-Fc fusion protein. N. Engl. J. Med. (1997) 337:141-147.
38. MORELAND LW, SCHIFF MH, BAUMGARTNER SW et al.: Etanercept therapy in rheumatoid arthritis: a randomized, controlled study. Ann. Intern Med. (1999) 130: 478-486.
39. MORELAND LW, COHEN SB, FLEISCHMANN RM, BAUMGARTNER SW, SCHIFF MH et a.: Safety and efficacy of up to 5 years of etanercept (Enbrel) therapy in rheumatoid arthritis [abstract]. Ann. Rheum. Dis. (2002) 61(Suppl. 1):FR10078.
40. WEINBLATT ME, KEYSTONE EC, FURST DE et al.: Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant METHOTREXATE: the ARMADA trial. Arthritis Rheum. (2003) 48:35-45.
41. MAINI R, ST CLAIR EW, BREEDVELD F et al.: Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet (1999) 354:1932-1939.
42. KLARESKOG L, VAN DER HEIJDE D, DE JAGER JP et al.: TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study investigators. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet (2004) 363:675-681.
43. WEINBLATT ME, KREMER JM, BANKHURST AD et al.: A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N. Engl. J. Med. (1999) 340:253-259.
44. KREMER J, WEINBLATT M, BANKHURST AD et al. Etanercept added to background methotrexate therapy in patients with rheumatoid arthritis: continued observations. Arthritis Rheum (2003) 48:1493-1499.
45. VAN DER HEIJDE D, KLARESKOG L, WAJDULA J, PEDERSEN R, FATENEJAD S: Sustained halting of joint damage with combination etanercept and methotrexate: 3-year results from the TEMPO trial [abstract]. Ann. Rheum. Dis. (2006) 65(Suppl. 2):509
46. MARTIN MOLA E, VAN DER HEIJDE D, DE MELO GOMES J et al.: Sustained clinical efficacy and safety of combination therapy with etanercept plus methotrexate in RA patients through 4 years: TEMPO trial extension results [abstract]. Ann. Rheum Dis. (2006) 65(Suppl. 2):331.
47. VAN DER HEIJDE D, MARTÍN MOLA E, LUUKKAINEN R et al.: The addition of etanercept to methotrexate and methotrexate to etanercept monotherapies improves clinical efficacy in RA patients despite low moderate disease activity at baseline: results of the TEMPO extension trial (year 4) [abstract]. Ann. Rheum Dis. (2006) 65(Suppl 2):508
48. VAN VOLLENHOVEN R, ERNESTAM S, HARJU A, BRATT J, KLARESKOG L: Etanercept versus etanercept plus methorrexate: a registry based study suggesting that the combination is clinically more efficacious. Arthritis Res. Ther. (2003) 5: 347-351.
49. VAN RIEL PL, TAGGART AJ, SANY J et al.: Efficacy and safety of combination etanercept and methotrexate versus ecanercept alone in patients with rheumatoid arthritis with an inadequate response to Methotrexate: The ADORE study. Ann. Rheum Dis. (2006) 65:1478-1483.
50. BATHON JM, MARTIN RW, FLEISCHMANN RM et al.: A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N. Engl. J. Med. (2000) 343:1586-1593.
51. GENOVESE M, BATHON J, MARTIN R et al.: Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum. (2002) 46:1443-1451.
52. GENOVESE MC, BATHON JM, FLEISCHMANN RM et al.: Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis. J. Rheumatol. (2005) 32:1232-1242.
53. ERRA A, MORENO E, GUANHON L et al.: Experience in the switch from infliximab to etanercept, or vice versa, in rheumatoid arthritis patients [abstract]. Ann. Rheum Dis. (2002) 61(Suppl. 1):379.
54. BUCH MH: Do patients with rheumatoid arthritis with high disease activity on infliximab demonstrate improvement on etanercept? [abstract]. Ann. Rheum. Dis. (2003) 62(Suppl. 1):181.
55. HARAOUI B, KEYSTONE EC, THORNE JC et al.: Clinical outcomes of patients with rheumatoid arthritis after switching from infliximab to etanercept. J. Rheumatol. (2004) 31:2356-2359.
56. VAN VOLLENHOVEN R, HARJU A, BRANNEMARK S, KLARESKOG L: Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor α blockers can make sense. Ann. Rheum. Dis. (2003) 62:1195-1198.
57. IANNONE F, TROTTA F, MONTECUCCO C et al.: Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab due to side effects. Ann. Rheum Dis. (2007) 66:249-252.
58. LOVELL DJ, GIANNINI EH, REIFF A, CAWKWELL GD et al.: Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N. Engl. J. Med. (2000) 342:763-769.
59. LOVELL DJ, GIANNINI EH, REIFF A et al.: Pediatric Rheumatology Collaborative Study Group. Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial. Arthritis Rheum. (2003) 48:218-226.
60. LOVELL DJ, REIFF A. JONES OY et al.: Pediatric Rheumatology Collaborative Study Group. Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum. (2006) 56:1987-1994.
61. QUARTIER P, TAUPIN P. BOURDEAUT F et al.: Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum. (2003) 48:1093-101.
62. TWILTI M, CATE T, VAN ROSSUM MAJ, WULFFRAAT NM: Long term follow-up of etanercept in the treatment of juvenile idiopathic arthritis; the Dutch national study [abstract]. Ann. Rheum. Dis. (2006) 65(Suppl 2):572.
63. MEASE PJ, GOFFE BS, METZ J, VANDERSTOEP A, FINCK B, BURGE DJ: Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet (2000) 356:385-390.
64. MEASE PJ, KIVITZ RJ, BURCH FX et al.: Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum. (2004) 50:2264-2272.
65. MEASE PJ, KIVITZ RJ, BURCH FX et al.: Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. J Rheumatol. (2006) 33:712-721.
66. GORMAN JD, SACK KE, DAVIS JC: Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor a. N. Engl. J. Med. (2002) 346:1349-1356.
67. BRANDT J, KHARIOUZOV A, LISTING J et al.: Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum. (2003) 48:1667-1675.
68. BARALIAKOS J, BRANDT J, LISTING J et al.: Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data. Arthritis Rheum. (2005) 53:856-863.
69. DAVIS JC JR, VAN DER HEIJDE D et al.: Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum. (2003) 48: 3230-3236.
70. BARALIAKOS X, DAVIS J, TSUJI W, BRAUN J: Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor α receptor fusion protein etanercept. Arthritis Rheum. (2005) 52:1216-1223.
71. DAVIS JC, VAN DER HEIJDE DM, BRAUN J et al.: Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks. Ann. Rheum. Dis. (2005) 64:1557-1562.
72. CALIN A, DIJKMANS BA, EMERY P et al.: Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann. Rheum. Dis. (2004) 63:1594-600.
73. SIEPER J, DIJKMANS B.A.C, VAN DER LINDEN S et al. Long term efficacy and safety of etanercept in patients with ankylosing spondylitis: 148 to 160 week analysis from an ongoing trial [abstract]. Ann. Rheum. Dis. (2006) 65(Suppl. 2): 437.
74. VAN DER HEIJDE D, KLARESKOG L, BAKER P, WAJDULA J, FATENEJAD S: Etanercept combined with methotrexate is well tolerated for 3 years: results from the trial of etanercept and methotrexate with radiographic and patient outcomes (TEMPO) [abstract].. Ann. Rheum. Dis. (2006) 65(Suppl. 2):510.
75. FLEISCHMANN R, BAUMGARTNER SW, WEISMAN MH, LIU T, WHITE B, PELOSO P: Long term safety of etanercept in elderly subjects with rheumatic diseases. Ann. Rheum. Dis. (2006) 65:379-384.
76. ELLERIN T, RUBIN RH, WEINBLATT ME: Infections and anti-tumor necrosis factor α therapy. Arthritis Rheum (2003) 48:3013-3022.
77. KHANNA D, MCMAHON M, FURST DE: Safety of tumour necrosis factor-α antagonists. Drug Saf. (2004) 27:307-324.
78. KEYSTONE EC: Safety of biologic therapies-an update. J. Rheumatol. Suppl. (2005) 74:8-12.
79. MOHAN VR SCANGA CA, YU K et al.: Effects of tumor necrosis factor α on host immune response in chronic persistent tuberculosis: possible role for limiting pathology. Infect. Immun. (2001) 69:1847-55.
80. WALLIS RS, BRODER MS, WONG JY, HANSON ME, BEENHOUWER DO: Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin. Infect. Dis. (2004) 38:1261-1265.
81. WALLIS RS, BRODER M, WONG JY, BEENHOUWER DO: Granulomatous infections due to tumor necrosis factor blockade: correction. Clin. Infect. Dis. (2004) 39:1254-1255.
82. GOMEZ-REINO JJ, CARMONA L, VALVERDE VR MOLA EM, MONTERO MD; BIOBADASER GROUP: Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum. (2003) 48:2122-2127.
83. ASKLING J, FORED CM, BRANDT L et al.: Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum. (2005) 52:1986-1992.
84. WOLFE F, MICHAUD K, ANDERSON J, URBANSKY K: Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum. (2004) 50:372-379.
85. FURST DE, WALLIS R. BRODER M, BEENHOUWER DO: Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection. Semin. Arthritis Rheum. (2006) 36:159-167.
86. MARIETTE X, SALMON D AND GROUP RATIO: French guidelines for diagnosis and treating latent and active tuberculosis in patients with RA treated with TNF blockers. Ann. Rheum. Dis. (2004) 62:791.
87. FURST DE, CUSH J, KAUFMANN S, SIEGEL J, KURTH R: Preliminary guidelines for diagnosing and treating tuberculosis in patients with rheumatoid arthritis in immunosuppressive trials or being treated with biologic agents. Ann. Rheum. Dis. (2002) 61:62-63.
88. CARMONA L, GOMEZ-REINO JJ, RODRIGUEZ-VALVERDE V t al.; BIOBADASER GROUP: Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum. (2005) 52:1766-1772.
89. DIXON WG, WATSON K, LUNT M, HYRICH KL, SILMAN AJ, SYMMONS DP; BRITISH SOCIETY FOR RHEUMATOLOGY BIOLOGICS REGISTER: Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. (2006) 54:2368-2376.
90. LISTING J, STRANGFELD A, KARY S et al.: Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum. (2005) 52:3403-3412.
91. DESAI SB, FURST DE: Problems encountered during anti-tumour necrosis factor therapy. Best Pract. Res. Clin. Rheumatol. (2006) 20:757-790.
92. KEYSTONE EC: Safety of biologic therapies:an update. J. Rheumatol (2005) 32(Suppl. 74):8-12.
93. BROWN SL, GREENE MH, GERSHON SK, EDWARDS ET, BRAUN MM:Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum (2002) 46:3151-3158.
94. WOLFE F, MICHAUD K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum. (2004) 50:1740-1751.
95. ASKLING J, FORED CM, BRANDT L et al.: Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann. Rheum. Dis. (2005) 64:1421-6.
96. WOLFE F, MICHAUD K: The risk of lymphoma among persons with rheumatoid arthritis in the United States: no association with anti-TNF therapy [abstract]. Ann. Rheum. Dis. (2006) 65(Suppl. 2):512-513.
97. GEBOREK P, BLADSTROM A, TURESSON C et al.: Tumour necrosis factor blockers do not increase overall tumour risk in patient with rheumatoid arthritis, but may be associated with an increased risk of lymphoma. Ann. Rheum. Dis. (2005) 64:699-703.
98. WOLFE F, MICHAUD K: The association of new cases of cancer with biologic therapy [abstract]. Arthritis Rheum. (2006) 54(Suppl.):S549.
99. OKADA SK, SIEGEL JN: Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis. JAMA (2006) 296:2201-2202.
100. BONGARTZ T, SUTTON AJ, SWEETING MJ, BUCHAN I, MATTESON EL, MONTORI V: Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA (2006) 295:2275-2285.
101. STONE JH, HOLBROOK JT, MARRIOTT MA et al.: Wegener's Granulomatosis Etanercept Trial Research Group. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis Rheum. (2006) 54:1608-1618.
102. KHANNA D, MCMAHON M, FURST DE: Anti-tumor necrosis factor α. therapy and heart failure: what have we learned and where do we go from here?. Arthritis Rheum. (2004) 50:1040-1050.
103. DESWAL A, BOZKURT B, SETA Y, PARILTI-EISWIRTH S et al.: Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel,etanercept) in patients with advanced heart failure. Circulation (1999) 99:3224-3226.
104. BOZKURT B, TORRE-AMIONE G, WARREN MS et al.: Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure. Circulation (2001) 103:1044-1047.
105. COLETTA AP, CLARK AL, BANARJEE P, CLELAND JG: Clinical trials update: RENEWAL (RENAISSANCE and RECOVER) and ATTACH. Eur. J. Heart Fail. (2002) 4:559-561.
106. MANN DL, MCMURRAY JJ, PACKER M et al.: Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation (2004) 109:1594-602.
107. KWON HJ, COTE TF. CUFFE MS, KRAMER JM, BRAUN MM: Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann. Intern. Med. (2003) 138:807-811.
108. WOLFE F, MICHAUD K. Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am. J. Med. (2004) 116:305-311.
109. NELSON DR, LIM HL, MAROUSIS CG et al.: Activation of tumor necrosis factor-a system in chronic hepatitis C virus infection. Dig Dis. Sci. (1997) 42:2487-94.
110. PARKE FA, REVEILLE JD: Anti-tumour necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection. Arthritis Rheum. (2004) 51:800-804.
111. MAGLIOCCO MA, GOTTLIEB AB: Etanercept therapy for patients with psoriatic arthritis and concurrent hepatitis C virus infection: report of 3 cases. J. Am. Acad. Dermatol. (2004) 51:580-584.
112. KHANNA M, SHIRODKAR MA, GOTTLIEB AB: Etanercept therapy in patients with autoimmunity and hepatitis. J. Dermatolog. Treat. (2003) 14:229-232.
113. PETERSON JR, HSU FC, SIMKIN PA, WENER MH: Effect of tumour necrosis factor α antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection. Ann. Rheum. Dis. (2003) 62:1078-1082.
114. R0KHSAR C, RABHAN N, COHEN SR. Etanercept monotherapy for a patient with psoriasis, psoriatic arthritis, and concomitant hepatitis C infection. J. Am. Acad. Dermatol (2006) 54:361-362.
115. DE SIMONE C, PARADISI A, CAPIZZI R, CARBONE A, SICILIANO M, AMERIO PL: Etanercept therapy in two patients with psoriasis and concomitant hepatitis C. J. Am. Acad. Dermatol. (2006) 54:1102-1104.
116. ROUX CH, BROCQ O, BREUIL V. ALBERT C, EULLER-ZIEGLER L: Safety of anti-TNF-α therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis. Rheumatology (Oxford) (2006) 45:1294-1297.
117. MAROTTE H, FONTANGES E, BAILLY F, ZOULIM F, TREPO C, MIOSSEC P: Etanercept treatment for three months is safe in patients with rheumatological manifestations associated with hepatitis C virus. Rheumatology (Oxford) (2006) 46(1):97-99.
118. ZEIN NN AND ETANERCEPT STUDY GROUP: Etanercept as an adjuvant to interferon and ribavirin in treatment naïve patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebocontrolled study. J. Hepatol. (2005) 42:315-322.
119. NIEWOLD TB, GIBOFSKY A. Concomitant interferon-α therapy and tumor necrosis factor α inhibition for rheumatoid arthritis and hepatitis C. Arthritis Rheum. (2006) 54:2335-2337.
120. TORRE D, ZEROLI C, GIOLA M et al.: Serum levels of interleukin-1α, interleukin-1β, interleukin-6, and tumor necrosis factor in patients with acute viral hepatitis. Clin. Infect. Dis. (1994) 18:194-198.
121. FANG JW, SHEN WW, MEAGER A. LAU JY. Activation of the tumor necrosis Factor-α system in the liver in chronic hepatitis B virus infection. Am. J. Gastroenterol. (1996) 91:748-753.
122. CALABRESE LH, ZEIN N, VASSILOPOULOS D: Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection. Ann. Rheum. Dis. (2004) 63(Suppl. 2):18-24.
123. SELMAJ KW: Tumour necrosis factor and anti-tumour necrosis factor approach to inflammatory demyelinating diseases of the central nervous system. Ann. Rheum. Dis. (2000) 59(Suppl. 1):94-102.
124. LOCK C, OKSENBERG J, STEINMAN L: The role of TNFα and lymphotoxin in demyelinating disease. Ann. Rheum. Dis. (1999) 58(Suppl. 1):121-128.
125. MARTINEZ-TABOADA VM, VAL-BERNAL JF et al.: Demyelinating disease and cutaneous lymphocitic vascutitis after ecanercept therapy in a patient with rheumatoid arthritis. Scand. J. Rheumatol. (2006) 35:322-323.
126. AL SAIEG N, LUZAR MJ: Etanercept induced multiple sclerosis and transverse myelitis. J. Rheumatol. (2006) 33:1202-1204.
127. TITELBAUM DS, DEGENHARDT A, KINKEL RP: Anti-tumor necrosis factor α-associated multiple sclerosis. Am. J. Neuroradiol. (2005) 26:1548-1550.
128. KUNZMANN S, WARMUTH-METZ M, GIRSCHICK HJ: Cerebral demyelination in association with TNF-inhibition therapy in a 5-year-old girl with aseptic meningitis as the first symptom of Still's disease. Scand. J. Rheumatol. (2005) 34:76-78.
129. NOGUERA-PONS R, BORRAS-BLASCO J, ROMERO-CRESPO I, ANTON-TORRES R, NAVARRO-RUIZ A, GONZALEZ-FERRANDEZ JA. Optic neuritis with concurrent etanarcept and isoniazid therapy. Ann. Pharmacother. (2005) 39:2131-2135.
130. RICHEZ C, BLANCO P, LAGUENY A, SCHAEVERBEKE T, DEHAIS J: Neuropathy resembling CIDP in patients receiving tumor necrosis factor-α blockers. Neurology (2005) 64:1468-1470.
131. VAN DER LAKEN CJ, LEMS WF, VAN SOESBERGEN RM, VAN DER SANDE JJ, DIJKMANS BA. Paraplegia in a patient receiving anti-tumor necrosisfactor therapy for rheumatoid arthritis: comment on the article by Mohan et al. Arthritis Rheum. (2003) 48: 269-270.
132. SICOTTE NL, VOSKUHL RR: Onset of multiple sclerosis associated with anti-TNF therapy. Neurology (2001) 57:1885-1888.
133. MOHAN N, EDWARDS ET, CUPPS TR et al.: Demyelination occurring during anti-tumor necrosis factor a therapy for inflammatory arthritides. Arthritis Rheum. (2001) 44:2862-2869.
134. HORNEFF G, SCHMELING H, BIEDERMANN T et al.: Paediatric Rheumatology Collaborative Group: die German etanercept registry for treatment of juvenile idiopathic arthritis. Ann. Rheum. Dis. (2004) 63:1638-1644.
135. FURST DE, BREEDVELD FC, KALDEN JR et al.: Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006. Ann. Rheum. Dis. (2006) 65(Suppl. 3):2-15.
136. ETANERCEPT. (Enbrel) package insert (2003).
137. KLARESKOG L, WAJDULA J, YEH P, FATENEJAD S, ETANERCEPT STUDY 301 INVESTIGATORS: Low autoantibody and anti-etanercept antibody formation and lack of impact on clinical outcomes after five years of treatment with etanercept in patients with rheumatoid arthritis [abstract]. Arthritis Rheum. (2005) 52(Suppl. 1): 348.
138. CARAMASCHI P, BIASI D, COLOMBATTI M et al.: Anti-TNFα therapy in rheumatoid arthritis and autoimmunity. Rheumatol. Int. (2006) 26:209-214.
139. DE RYCKE L, BAETEN D, KRUITHOF E, VAN DEN BOSCH F, VEYS EM, DE KEYSER F: Infliximab, but not etanercept, induces IgM anti-doublestranded DNA autoantibodies as main antinuclear reactivity. Arthritis Rheum. (2005) 52:2192-201.
140. SHAKOOR N, MICHALSKA M, HARRIS CA, BLOCK JA. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet (2002) 359:579-580.
141. MOHAN AK EDWARDS ET, COTE TR, SIEGEL JN, BRAUN MM: Drug-induced systemic lupus erythematosus and TNF-α blockers. Lancet (2002) 360:646.
142. RICHEZ C, BLANCO P DUMOULIN C, SCHAEVERBEKE T: Lupus erythematosus manifestations exacerbated by etanercept therapy in a patient with mixed connective tissue disease. Clin. Exp. Rheumatol. (2005) 23:273.
143. LEPORE L, MARCHETTI F, FACCHINIS, LEONE V. VENTURA A. Drug-induced systemic lupus erythematosus associated with etanercept therapy in a child with juvenile idiopathic arthritis. Clin. Exp. Rheumatol. (2003) 21:276-277.
144. CARLSON E, ROTHFIELD N: Etanercept-induced lupus-like syndrome in a patient with rheumatoid arthritis. Arthritis Rheum. (2003) 48:1165-1166; author reply 1166.
145. CAIRNS AP, DUNCAN MK, HINDER AE, TAGGART AJ: New onset systemic lupus; erythematosus in a patient receiving etanercept for rheumatoid arthritis. Ann. Rheum. Dis. (2002) 61:1031-1032.
146. DE BANDT M, SIBILIA J, LE LOET X et al.: Club Rhumatismes et Inflammation. Systemic lupus erythematosus induced by anti-tumour necrosis factor α therapy. a French national survey. Arthritis Res. Ther. (2005) 7:545-551.
147. JONSDOTTIR T, FORSLID J, VAN VOLLENHOVEN A et al.: Treatment with tumour necrosis factor α antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies. Ann. Rheum. Dis. (2004) 63:1075-1078.
148. MORELAND LW. BAUMGARTNER SW, SCHIFF MH et al.: Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N. Engl. J. Med. (1997) 337:141-147.
149. ROUX CH, BROCQ O, BREUIL V, ALBERT C, EULLER-ZIEGLER L: Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF)-{α} therapy. Rheumatology (Oxford) (2006) 46(4):695-698.
150. CARTER JD, VALERIANO J, VASEY FB: Tumor necrosis factor-α inhibition and VATER association: a causal relationship. J. Rheumatol. (2006) 33:1014-1017.
151. SILLS ES, PERLOE M, TUCKER MJ, KAPLAN CR, PALERMO GD: Successful ovulation induction, conception, and normal delivery after chronic therapy with etanercept: a recombinant fusion anti-cytokine treatment for rheumatoid arthritis. Am. J. Reprod. Immunol. (2001) 46:366-368.
152. WALLACE DJ, WEISMAN MH: The use of etanercept and other tumor necrosis factor-α blockers in infertility:it's time to get serious. J. Rheumatol. (2003) 30:1897-1899.
153. RUMP JA, USADE S, SCHONBORN H: Pregnancy and etanercept - two cases and follow up [abstract]. Proc. Eur. League Against Rheum. (2004) 63(Suppl. 1): THU0248.
154. FEYERTAG J, DINHOF G, SALZER H, DUNKY A. Pregnancy in a rheumatoid arthritis patient treated with Etanercept. Proc. Eur. League Against Rheum. (2004) 63(Suppl. 1):THU0297.
155. CHAKRAVARTY EF, SANCHEZ-YAMAMOTO D, BUSH TM: The use of disease modifying antirheumatic drugs in women with rheumatoid arthritis of childbearing age: a survey of practice patterns and pregnancy outcomes. J. Rheumatol. (2003) 30:241-6.
156. HYRICH KL, SYMMONS DP, WATSON KD, SILMAN AJ; BRITISH SOCIETY, FOR RHEUMATOLOGY BIOLOGICS REGISTER. Pregnancy outcome in women who were exposed to anti-tumor necrosis factor agents: results from a national population register. Arthritis Rheum. (2006) 54:2701-2702.
157. ELLISH NJ, SABODA K, O'CONNOR J, NASCA PC, STANEK EJ, BOYLE C: A prospective study of early pregnancy loss. Arthritis Rheum. (1996)
158. ZINAMAN MJ, CLEGG ED, BROWN CC, O'CONNOR J, SELEVAN SG: Estimates of human fertility and pregnancy loss. Fertil. Steril. (1996) 65:503-509.
159. CHAMBERS CD, JOHNSON DL, JONES KL, THE OTIS COLLABORATIVE RESEARCH GROUP: Pregnancy outcome in women exposed to anti-TNF-α medications: the OTIS Rheumatoid Arthritis in Pregnancy Study [abstract]. Arthritis Rheum. (2004) 50(Suppl.): S479-S480.
160. CHAKRAVARTY EF, NELSON L, KRISHNAN E: Obstetric hospitalizations in the United States for women with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum. (2006) 54:899-907.
161. SKOMSVOLL JF, OSTENSEN M, IRGENS LM, BASTE V: Obstetrical and neonatal outcome in pregnant patients with rheumatic disease. Scand. J. Rheumatol. Suppl. (1998) 107:109-112.
162. BOWDEN AP, BARRETT JH, FALLOW W, SILMAN AJ: Women with inflammatory polyarthritis have babies of lower birth weight. J. Rheumatol. (2001) 28:355-359.
163. NELSON JL, OSTENSEN M: Pregnancy and rheumatoid arthritis. Rheum. Dis. Clin. North Am. (1997) 23:195-212.